U.S. markets closed

  • S&P 500

    4,280.70
    +14.21 (+0.33%)
     

  • Dow 30

    34,433.84
    +237.02 (+0.69%)
     

  • Nasdaq

    14,360.39
    -9.32 (-0.06%)
     

  • Russell 2000

    2,334.40
    +0.77 (+0.03%)
     

  • Crude Oil

    74.00
    +0.70 (+0.95%)
     

  • Gold

    1,781.80
    +5.10 (+0.29%)
     

  • Silver

    26.19
    +0.14 (+0.54%)
     

  • EUR/USD

    1.1939
    +0.0004 (+0.04%)
     

  • 10-Yr Bond

    1.5360
    +0.0490 (+3.30%)
     

  • GBP/USD

    1.3880
    -0.0041 (-0.29%)
     

  • USD/JPY

    110.7600
    -0.0750 (-0.07%)
     

  • BTC-USD

    33,092.54
    +2,053.69 (+6.62%)
     

  • CMC Crypto 200

    765.98
    -76.67 (-9.10%)
     

  • FTSE 100

    7,136.07
    +26.10 (+0.37%)
     

  • Nikkei 225

    29,066.18
    +190.95 (+0.66%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DNMR, WPG and FREQ

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / June 27, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Danimer Scientific, Inc. (NYSE:DNMR)
Class Period: October 5, 2020 - May 4, 2021
Lead Plaintiff Deadline: July 13, 2021

The DNMR lawsuit alleges Danimer Scientific, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Danimer had deficient internal controls; (ii) as a result, the Company had misrepresented, inter alia, its operations' size and regulatory compliance; (iii) Defendants had overstated Nodax's biodegradability, particularly in oceans and landfills; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in DNMR: https://www.kleinstocklaw.com/pslra-1/danimer-scientific-inc-loss-submission-form?id=17197&from=1

Washington Prime Group, Inc. (NYSE:WPG)
Class Period: November 5, 2020 - March 4, 2021
Lead Plaintiff Deadline: July 23, 2021

The complaint alleges that during the class period Washington Prime Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) WPG's financial condition was deteriorating substantially; (2) as a result, there was substantial uncertainty about the Company's ability to meet its capital structure obligations as they became due; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in WPG: https://www.kleinstocklaw.com/pslra-1/washington-prime-group-inc-loss-submission-form?id=17197&from=1

Frequency Therapeutics, Inc. (NASDAQ:FREQ)
Class Period: November 16, 2020 - March 22, 2021
Lead Plaintiff Deadline: August 2, 2021

The FREQ lawsuit alleges that Frequency Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

Learn about your recoverable losses in FREQ: https://www.kleinstocklaw.com/pslra-1/frequency-therapeutics-inc-loss-submission-form?id=17197&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/653248/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-DNMR-WPG-and-FREQ

Recommended Stories

  • Hertz Is About to Exit Bankruptcy. Why Its Stock Is a Buy.

    The car-rental leader will emerge from bankruptcy with a strong balance sheet and the potential to prosper on a surge in travel.

  • 3 Vanguard Funds Rated 5 Stars by Morningstar

    Learn about three Vanguard funds that have a five-star rating from Morningstar that specialize in investing in specific niches of the securities market.

  • Billionaire Leon Cooperman is Crazy About these 10 Stocks

    In this article, we examined Billionaire Leon Cooperman’s portfolio management strategy and why Billionaire Leon Cooperman is crazy about these 10 stocks. If you want to skip our detailed analysis of Cooperman’s history and hedge fund performance, go directly to Billionaire Leon Cooperman is Crazy About these 5 Stocks. The hedge fund manager and American […]

  • Intellia Stock Could Surge 35-45% After Positive Gene Editing Data, Says Analyst

    Intellia Therapeutics (NTLA) investors probably can't wait for the new week to kick into action. On Saturday, the company released interim data from the Phase 1 trial of its collaboration with Regeneron on an experimental therapy for transthyretin amyloidosis (ATTR) – a protein misfolding disorder. The data showed that for the six people that received a single 0.3 mg/kg dose of NTLA-2001, there was an 87% mean reduction in serum TTR, while there was a maximum 96% serum TTR reduction following a

  • 10 Best Dividend Stocks to Buy According to Billionaire Ken Griffin

    In this article, we will discuss the 10 best dividend stocks to buy according to billionaire Ken Griffin. If you want to skip our detailed analysis of Griffin’s history and hedge fund performance, go directly to the 5 Best Dividend Stocks to Buy Now According to Billionaire Ken Griffin. The self-made billionaire Ken Griffin began investing in […]

  • WallStreetBets is dying, long live the WallStreetBets movement

    The mothership message board is less popular than ever among die-hard retail investors, and that could be great news for the future of retail investing.

  • Warren Buffett's top 8 lessons from the COVID-19 pandemic

    The legendary investor says these are the key takeaways for investors and consumers.

  • The S&P 500 Is at New Highs. Here’s What the Charts Say Happen Next.

    The S&P 500's move on Thursday signals the potential for more gains, technical analyst say, but the ride could be bumpy.

  • Nano-X Imaging Scanning for FDA Approval

    Within the realm of publicly traded healthcare companies, the price action of biotech firms somewhat mimics that of typical pharmaceuticals: both bounce up and down based off FDA filings and approval stages. This is true as well for Nano-X Imaging Ltd. (NNOX), an Israeli medical imaging technology company, which has seen its share price swing dramatically since its August 2020 IPO. (See Nano-X Imaging stock charts on TipRanks) Rahul Rakhit of LifeSci Capital covered recent updates in his report,

  • Peter Thiel turned his Roth IRA into a pot of gold. You can too, but tread carefully

    Peter Thiel transformed a tiny Roth IRA worth approximately $2,000 into a $5 billion tax-free behemoth, according to an article from the investigative news site ProPublica. “You would have to tread very carefully,” said Michelle Gessner of Gessner Wealth Strategies in Houston, Texas. “I don’t think it’s impossible for the average person to do their own smaller scale version of it,” said Malcolm Ethridge, executive vice president at CIC Wealth in Rockville, Md., and host of The Tech Money podcast.

  • Do you really need a financial adviser? Take this six-question test to find out.

    Whether you’re 27 and starting a career or 57 and planning for retirement, you may wonder, “Do I need to hire a financial planner?” Will paying an adviser’s fee result in substantially better financial decisions and fewer costly mistakes? If you’re a diligent saver and competent investor, you may figure there’s little reason to purchase an adviser’s services. If you don’t know something, such as whether converting to a Roth IRA makes sense or not, you’re comfortable researching the answer on your own.

  • Starved for Income? Consider These 4 Funds.

    U.S. government securities yield less than nothing, if you consider the effects of inflation, and stocks are high. Closed-end funds may be one of the few vehicles that can produce steady income.

  • SoFi Stock Looks Like a Good Value Below $21

    SoFi Technologies (NASDAQ:SOFI) still looks like good value here now that it is public, which allowed it to receive $1.91 billion in additional cash. Moreover, on May 24, the company produced its 10-Q filing, and on May 31 it sent out an investor presentation. (For some odd reason, the company did not produce an actual earnings release, just a slide presentation.) Nevertheless, SOFI stock is still worth between $23.91 and $27.80. Source: rafapress / Shutterstock.com This means the stock, at $20.

  • Big Banks Seen Increasing Dividends by 10% on Average

    Barclays analyst Jason Goldberg highlights potential payouts from Wells Fargo, Goldman Sachs, and Morgan Stanley.

  • Rally Has Led Investors Astray on Yield, Says Dividend Fund Vet. Here Are Some Bargains.

    While heady stock market gains have diminished investors’ attention on yield, T. Rowe Price Equity Income fund manager John Linehan thinks that’s a mistake.

  • Micron Earnings Are Coming; Here’s What Matters

    Memory giant Micron (MU) will take center stage next week when it delivers May quarter (F3Q) results on Wednesday (June 30, AMC). As the company already made a positive preannouncement on the quarter’s action a few weeks ago, Deutsche Bank’s Sidney Ho isn’t anticipating “many surprises.” Micron sees revenue coming in at or even above the high end of the original $6.9-7.3 billion range it guided for, while EPS (between $1.55-1.69) and gross margins are also expected to put in a strong display. “T

  • The Outlook of Coupang Stock Is Quite Strong

    Coupang (NYSE:CPNG), a leading South Korean e-commerce company, has developed attractive new services and has decided to expand to multiple, new geographic markets. As a result, I expect CPNG stock to meaningfully outperform the market over the longer term. Source: Ki young / Shutterstock.com What’s more, Coupang’s decision to enter the third-party logistics market should be very positive for its shares, while the company’s valuation appears to have significant room to expand. InvestorPlace - St

  • Haters Everywhere in Stock Market After S&P 500’s Big First Half

    (Bloomberg) -- People were already worried about equities six months ago. Now, after the S&P 500 Index defied everything from nosebleed valuations to inflation to post one of the best first halves ever, they’re downright paranoid.Wall Street strategists, never ones to restrain their enthusiasm when it’s warranted, warn that the gains have played out. Short sellers are circling, with wagers against the largest equity exchange-traded fund rising to the highest level this year. Star investors like

  • Bank of America Climbing on COVID-19 Rule Rollbacks

    Up more than 35% so far this year, does Bank of America (BAC) stock have room to climb? Or does recent volatility signal a reversal to the rebound of the money center bank’s shares? Recent talk by the U.S. Federal Reserve about raising rates sooner than expected in order to combat inflation, may have markets worried. Specifically for banks, the additional flattening of the yield curve is a near-term concern as well. However, a “return to normal” for interest rates bodes well in the long-term for

  • Trail of Brothers Linked to Missing Bitcoin Stash Is Still Murky

    (Bloomberg) -- The Cajee brothers, who ran a cryptocurrency investment platform from South Africa that the local regulator suspects of being a Ponzi scheme, are confounding both their family and desperate investors alike.It’s still hard to establish the whereabouts of Ameer and Raees Cajee, the pair that operated Johannesburg-based Africrypt since 2019. They appear to have vanished, along with an estimated $3.6 billion in Bitcoin -- an amount that a lawyer for the brothers said was inflated.Atto